Grufity logo
Grufity logo
FGEN

FGEN - FibroGen Inc Stock Price, Fair Value and News

$86.10-0.20 (-0.23%)
Market Closed as of 31 Jul 2026, 04:05 pm ET

7/100

FGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

7/100

FGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FGEN Price Action

Last 7 days

1.1%

Last 30 days

1.8%

Last 90 days

18.2%

Trailing 12 Months

2.9%

FGEN RSI Chart

FGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FGEN Valuation

Market Cap

349.4M

Price/Earnings (Trailing)

2.14

Price/Sales (Trailing)

46.96

EV/EBITDA

-6.6

Price/Free Cashflow

-16.32

FGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

FGEN Fundamentals

FGEN Revenue

Revenue (TTM)

7.4M

Rev. Growth (Yr)

36.47%

Rev. Growth (Qtr)

192.72%

FGEN Earnings

Earnings (TTM)

163.6M

Earnings Growth (Yr)

-427.61%

Earnings Growth (Qtr)

-6.88%

FGEN Profitability

Operating Margin

40.71%

EBT Margin

-761.70%

Return on Equity

-531.74%

Return on Assets

149.24%

Free Cashflow Yield

-6.13%

FGEN Investor Care

Shares Dilution (1Y)

0.25%

Diluted EPS (TTM)

40.45

Revenue & Growth

How FibroGen Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20267.4M---
20257.0M7.3M8.3M6.4M
202442.5M38.2M33.9M29.6M
2023116.1M130.6M155.0M46.8M
2022257.7M263.1M122.9M140.7M
2021190.3M171.8M283.8M235.3M
2020257.1M108.4M119.3M176.3M
2019204.9M352.5M356.7M256.6M
2018133.5M147.2M135.6M213.0M
2017184.3M125.3M135.8M131.0M
2016192.8M161.5M172.1M183.2M
2015136.0M166.6M172.5M180.8M
2014111.0M119.9M128.7M137.6M
2013---102.2M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About FibroGen Inc

FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
 WEBSITEfibrogen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES592

FibroGen Inc Frequently Asked Questions

FGEN is the stock ticker symbol of FibroGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of FibroGen Inc is 349.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, FGEN's PE ratio (Price to Earnings) is 2.14 and Price to Sales (PS) ratio is 46.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FGEN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, FibroGen Inc has provided -0.018 (multiply by 100 for percentage) rate of return.